A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity

  • Cell Discov. 2020 Jul 28;6(1):49. doi: 10.1038/s41421-020-0181-z.
Adam M Burgoyne  #  1 ,  Kendra R Vann  #  2 ,  Shweta Joshi  3 ,  Guillermo A Morales  4 ,  Francisco M Vega  3  5 ,  Alok Singh  3 ,  Dhananjaya Pal  3 ,  Aran B Merati  1 ,  Tatiana G Kutateladze  2 ,  Donald L Durden  3  4
Affiliations
  • 1. Division of Hematology-Oncology, Department of Medicine, Moores Cancer Center, University of California San Diego, La Jolla, CA USA.
  • 2. Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO USA.
  • 3. Division of Pediatric Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, La Jolla, CA USA.
  • 4. SignalRx Pharmaceuticals, San Diego, CA USA.
  • 5. Department of Cell Biology, Instituto de Biomedicina de Sevilla, Universidad de Sevilla, Sevilla, Spain.
  • # Contributed equally.
PMID: 32793389 DOI: 10.1038/s41421-020-0181-z
Keywords
Cancer therapy; Epigenetics; X-ray crystallography.
Products